The FDA approved Insulin glargine, Lixisenatide for medical use on 21st, Nov 2016 for Type 2 diabetes.

A 2022 study evaluated the efficacy of Insulin Glargine and Lixisenatide in adults with type 2 diabetes. The study found that Insulin Glargine and Lixisenatide significantly improved glycemic control by reducing HbA1c levels without causing weight gain. Additionally, the study reported a low risk of hypoglycemia.

Insulin glargine, Lixisenatide, is used to control blood sugar levels and elevate the production of insulin in the body. It also helps to slow down glucose absorption from foods. It aids in treating type 2 diabetes in adults and controls blood sugar when it becomes abnormal. If other medicines fail to treat or control high blood glucose levels, Insulin glargine, Lixisenatide can be given along with metformin and/or sodium-glucose co-transporter-2 (SGLT2) inhibitors.

Insulin glargine, Lixisenatide, is available as an injection for subcutaneous use to be administered by your healthcare provider. Your doctor will decide the most suitable dosage for your case according to your age and physical circumstances.

The common side effects that are experienced while you are on the treatment with Insulin glargine, Lixisenatide are dizziness, feeling sick, vomiting, injection site reaction, headache, diarrhea, respiratory tract infection (cold or sore throat). Consult your doctor immediately if you have low blood sugar (hypoglycemia).

Inform your doctor if you are an elderly patient or have a kidney or liver problem, which will help them to adjust the dose accordingly. The safety and efficacy of the medicine in children and adolescents under 18 years of age have not been established. Inform your doctor if you have a history of alcoholism before using the medicine. Drinking alcohol during the treatment can either raise or lower your blood sugar level. Insulin glargine, Lixisenatide may cause side effects like dizziness or you may have an risk of low blood sugar level which can affect the ability of driving. It is recommended to speak with your doctor for further details.

Follow these precautions while using Insulin glargine, Lixisenatide: 

• Hypoglycemia: Avoid using this medication during episodes of low blood sugar. Monitor blood glucose levels closely, especially when adjusting the insulin regimen.
• Hypersensitivity reactions: Discontinue use if severe allergic reactions, including anaphylaxis, occur.
• Pancreatitis: Consider alternative antidiabetic therapies for patients with a history of pancreatitis.
• Kidney and liver disease: Use this medication with caution in patients with kidney or liver disease.

Drinking enough water is recommended to compensate for the water loss during diarrhea or vomiting. Following a diet with less sugar and regular exercise can help you improve the treatment output and manage diabetes. It is recommended to speak with your doctor about your diabetes symptoms to get an appropriate treatment for your diabetic type.

1. Sanofi-Aventis Deutschland GmbH, European Medicines Agency (EMA), [Revised on 18 July 2024] [Accessed on 21 May 2024], Suliqua, INN-insulin glargine+lixisenatide (europa.eu)
2. Sanofi-aventis, US Food and Drug Administration, FDA [Revised on July 2021] [Accessed on 21st May 2024], https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208673s013lbl.pdf
3. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Hormones and Hormones Antagonists, 13th edition, 2011, 871 & 877.
4. Candido, R., Modugno, M., Larosa, M. et al. Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study. Diabetes Ther 14, 77–92 (2023). https://doi.org/10.1007/s13300-022-01328-7

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.